A woman aged 62 was referred with a 12-year history of extreme fatigue, myalgias in the arms and legs and insomnia alternating with hypersomnia. The duration of the illness puts her at the severe end of the CFS spectrum, since the mean duration of illness seen in a tertiary referral centre is typically 3±4 years. The onset was associated with the breakdown of her marriage, and 7 years after the onset of her primary complaints she developed persistently low mood and loss of motivation in the absence of any impairment of appetite or of self-neglect. There was never any history of suicidal thoughts or urges. Her depressive symptoms responded to lofepramine 140 mg daily and she was able to return to work. The depressive symptoms recurred within a year and again responded to lofepramine. In 1995, further depressive symptoms did not respond to lofepramine but on referral to the psychiatric service she was informed that there was no evidence of a primary psychiatric disorder. After medical assessment in May 1997 she was formally diagnosed as having chronic fatigue syndrome, according to the Oxford criteria 1 . On examination in January 1998 there were no discernible psychiatric symptoms and her mental state was normal. It was decided to embark upon a programme of carefully graded exercise to increase her exercise tolerance. At this stage, the patient had been off treatment for 3 years and neuroendocrine tests could be conducted without the confounding effects of medication (including hormone replacement therapy). Neuroendocrine (prolactin) responses to oral buspirone (30 mg) and indices of mood (Hospital Anxiety and Depression Scale [HAD]) were assessed before treatment, 12 months into the graded exercise, and at discharge (18 months). A treadmill walking test was conducted to assess her ability to undertake aerobic exercise and set the starting exercise prescription at an appropriate level. This involved the patient walking at a constant 5 km/h, the slope being increased by 1.5% every 2 min. The patient was encouraged to continue to her perceived maximum capacity. Heart rate was monitored throughout by telemetry. Thereafter, she was given an ambulatory heart rate monitor and was initially prescribed 5 min daily walking at approximately 65% of the maximum heart rate achieved in the treadmill test. This was progressively increased by 2±3 min every week. Neuroendocrine function was assessed by measurement of prolactin release half-hourly for 4 hours after oral buspirone 30 mg.
A strategy of careful graded exercise substantially improved the patient's exercise tolerance and clinical symptoms. By 6 months into the graded exercise rehabilitation, she was walking an average of 20 min per day, and at 12 months this had increased to 40 min (Figure but twelve months into exercise these values were much lower (604 mIU/L,3202 mIUL 71 6h) ( Figure 2 ).
Over this 12-month period the patient described improvements in her self-con®dence, greater interest in her appearance and less need to sleep during the day to sustain evening activity. The increased con®dence in her physical capabilities enabled her to widen her social activities and she started weekly swimming lessons. At 18 months into the exercise rehabilitation programme, she was able to move house and was discharged. The prolactin response to buspirone and HAD scores reached their lowest levels at this time (peak prolactin 350 mIU/L; depression 9/anxiety 6) and were strongly correlated throughout.
COMMENT
The current guidelines for diagnosis of CFS in the UK do not exclude depressive illness or anxiety disorders 1 . In line with previous observations 2 , our patient showed a higher stress hormone response to an oral 5-hydroxytryptamine agonist challenge than that seen in healthy controls, whereas in major depression such responses are much lower 3 .
The differences in hypothalamic function between CFS and depressive disorders suggest that the affective symptoms experienced by many CFS patients have a different neurobiological basis from that of major depression. Diurnal variation also seems to differ between CFS and classic depression 4 . The hypothalamic±pituitary± adrenal axis has a central role in the body's response to stress, whether physical or psychological. The hypothalamic 5-hydroxytryptamine sensitivity observed in CFS may re¯ect a pathological adaptation, leading to an altered perception of effort. This may explain why CFS patients often respond to mild physical activity in the way that their healthy counterparts would respond to major sustained exertion. At present few speci®c therapies other than cognitive behaviour therapy are available for CFS. However, it is noteworthy that, in some patients, graded exercise has been reported to be clinically bene®cial as a management strategy 5 . With a carefully graded exercise programme, our CFS patient experienced physical and psychological bene®ts that were re¯ected by a progressive reduction in her previously sensitive prolactin response to buspirone.
Although there is great variation in women's prolactin responses to buspirone, these are largely menstrual cycle dependent 6 . Our own preliminary work has shown that, in the absence of exercise therapy, the buspirone challenge is fairly reproducible in postmenopausal women, with coef®cients of variation for three prolactin responses conducted over 18 months of 4.8%, 11.48% and 13.47% (n=3, average age 58 years). Clearly, the large changes observed in the current study cannot be explained in terms of variability with repeated testing. We conclude that the high stress response to buspirone in this CSF patient was a state-dependent abnormality reversed by rehabilitation. 
